Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis
Status:
Completed
Trial end date:
2022-06-18
Target enrollment:
Participant gender:
Summary
Background and aim: Hyperinflammatory host response associated with diabetes mellitus
significantly provokes periodontal tissue destruction. In this context, supporting the
standard treatment of periodontitis in diabetics with host modulation agents is a current
field of study.
This clinical study aims to investigate the clinical efficacy of melatonin supplementation in
non-surgical periodontal treatment in patients with Type 2 DM and periodontitis and its
biological basis (clinical effectiveness) based on some basic markers.
Material and method: In this randomized controlled and double-blind study, 27 of 55 patients
with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone and
28 of them were administered melatonin (6 mg daily, for 30 days) in addition to fmSRP. The
possible therapeutic contribution of melatonin was evaluated clinically and biochemically
[gingival crevicular fluid (GCF) RANKL, OPG and MMP-8 and serum IL-1β levels] at 3 and 6
months.